muk nine b: optimum, paving the way to effectively treat newly diagnosed high-risk mm
Published 6 years ago • 246 plays • Length 3:25Download video MP4
Download video MP3
Similar videos
-
2:55
molecular therapy stratification for high-risk mm: muk nine b optimum
-
1:23
management of high-risk newly diagnosed mm
-
1:58
high-risk myeloma and muk nine
-
8:13
treatment strategies for high-risk mm
-
1:48
muk nine study: what about tolerability?
-
5:19
a 17-year fight against multiple myeloma
-
4:54
introduction to nk cell immunotherapy with inkmune - priming nk cells
-
9:25
mgus diagnosis: a step-by-step approach
-
4:08
muk nine b update: dara-cvrd induction plus dara-vrd consolidation for ultra-high risk ndmm and ppcl
-
5:28
muk nine: tailoring treatment for patients high-risk ndmm
-
2:46
managing patients with high-risk myeloma
-
2:02
rwd from insight-mm: duration of therapy and treatment sequencing
-
4:00
immunotherapies for the treatment of high-risk mm
-
1:03
updated results of hyper-cvad and blinatumomab /- inotuzumab ozogamicin in newly-diagnosed b-all
-
2:06
an insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (mpn-u)
-
2:26
optimum/muknine: the risk of early relapse in patients with ultra high-risk multiple myeloma
-
2:44
myeloma qol through induction and maintenance
-
11:27
jesús san miguel: is myeloma curable?
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
2:51
komet-008: a phase i trial of ziftomenib combinations in kmt2a-rearranged or npm1-mutant aml
-
3:12
real-world daratumumab monotherapy